We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+20.44%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$504M
AUM Growth
+$16.8M
Cap. Flow
-$13M
Cap. Flow %
-2.59%
Top 10 Hldgs %
59.9%
Holding
52
New
17
Increased
6
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$26.4M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$23.2M
3
PTCT icon
PTC Therapeutics
PTCT
+$17.8M
4
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$13M
5
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$8.5M

Top Sells

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$27.7M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$20.4M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$17.6M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$15.9M
5
TRVN
Trevena, Inc.
TRVN
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 72.8%
2 Technology 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
1
DELISTED
Adamas Pharmaceuticals
ADMS
$45.5M 9.04%
2,601,351
– –
CNCE
2
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$37.5M 7.45%
+2,200,000
New +$26.4M
SGYP
3
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$33.7M 6.69%
7,223,509
+2,250,000
+45% +$13M
VNDA icon
4
Vanda Pharmaceuticals
VNDA
$307M
$31.3M 6.21%
2,232,238
+222,238
+11% +$3.17M
RIGL icon
5
Rigel Pharmaceuticals
RIGL
$681M
$30.1M 5.99%
+910,569
New +$23.2M
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
$26.5M 5.26%
2,440,959
– –
RXDX
7
DELISTED
Ignyta, Inc.
RXDX
$26.4M 5.25%
3,071,300
-928,700
-23% -$6.79M
TXMD icon
8
TherapeuticsMD
TXMD
$23.5M
$24.9M 4.95%
69,205
+3,685
+6% +$1.14M
NBIX icon
9
Neurocrine Biosciences
NBIX
$16.8B
$24.2M 4.82%
560,000
-190,000
-25% -$8.14M
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$21.4M 4.26%
301,809
-83,874
-22% -$4.91M
SAGE
11
PUT
DELISTED
Sage Therapeutics
SAGE
$21.3M 4.23%
+300,000
New +$17.6M
FOMX
12
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$18.2M 3.62%
3,681,708
+681,708
+23% +$6.56M
DBVT
13
DBV Technologies
DBVT
$799M
$17.1M 3.4%
48,592
+11,592
+31% +$4.07M
AVXS
14
DELISTED
AveXis, Inc. Common Stock
AVXS
$15.2M 3.02%
200,000
-213,179
-52% -$13.2M
PTCT icon
15
PTC Therapeutics
PTCT
$5.64B
$14.4M 2.87%
+1,468,521
New +$17.8M
ALNY icon
16
CALL
Alnylam Pharmaceuticals
ALNY
$27.5B
$12.8M 2.54%
+250,000
New +$11.6M
GBT
17
DELISTED
Global Blood Therapeutics, Inc.
GBT
$11.1M 2.2%
300,000
-700,000
-70% -$17.6M
PRTK
18
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.4M 2.06%
+539,571
New +$8.5M
ACOR
19
PUT
DELISTED
Acorda Therapeutics
ACOR
$9.08M 1.8%
+3,604
New +$10.4M
NDRM
20
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$8.36M 1.66%
+314,724
New +$7.8M
APYX icon
21
Apyx Medical
APYX
$173M
$8.16M 1.62%
3,055,000
– –
XLRN
22
DELISTED
Acceleron Pharma
XLRN
$7.94M 1.58%
+300,000
New +$7.91M
AUPH icon
23
Aurinia Pharmaceuticals
AUPH
$1.91B
$7.34M 1.46%
+1,000,000
New +$4.62M
VIRX
24
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$6.3M 1.25%
43,939
– –
FPRX
25
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$5.61M 1.11%
+155,265
New +$6.84M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2017 Portfolio in Review

As of Q1 2017, Great Point Partners held 52 positions worth $504M, up 3.4% from $487M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Great Point Partners's Q1 2017 filing shows 17 new, 6 increased, 8 reduced and 15 closed positions. Its largest new stake was Concert Pharmaceuticals, Inc.: 2,200,000 shares worth $37.5M. The largest sale was Enanta Pharmaceuticals, an estimated $27.7M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 81% a quarter earlier, followed by Technology.

  • Great Point Partners's largest Q1 2017 buy was Concert Pharmaceuticals, Inc.: 2,200,000 shares worth $37.5M.
  • Great Point Partners added most to Synergy Pharmaceuticals, Inc Common Stock in Q1 2017, an estimated $13M increase.
  • Great Point Partners's biggest Q1 2017 reduction was Global Blood Therapeutics, Inc., cutting an estimated $17.6M.
  • Great Point Partners fully exited Enanta Pharmaceuticals in Q1 2017, selling an estimated $27.7M.
  • Great Point Partners's ten largest holdings make up 60% of its $504M portfolio in Q1 2017.
  • Great Point Partners opened 17 new positions and closed 15 in Q1 2017.
  • Great Point Partners's portfolio value rose 3.4% quarter-over-quarter to $504M.

Based on Great Point Partners's 13F filing for Q1 2017, filed 15 May 2017.